HF 0420

Drug Profile

HF 0420

Alternative Names: HF0420; Oligotropin

Latest Information Update: 16 Oct 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Loyola University Chicago
  • Developer Hunter-Fleming; Loyola University Chicago
  • Class Glycosaminoglycans; Heparins; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Peripheral nervous system diseases
  • Discontinued Alzheimer's disease; CNS trauma; Stroke

Most Recent Events

  • 14 Oct 2009 Newron returns HF 0420 rights to inventor, Umberto Cornelli of Loyola University
  • 05 Apr 2006 This compound is still in active development for Alzheimer's disease
  • 03 Apr 2006 Preclinical trials in CNS trauma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top